Results 171 to 180 of about 331,968 (290)
Falling and Landing Framework (FLF): A Consensus on a Novel Falling and Landing Video Analysis Framework for Use Across Rugby Codes. [PDF]
Eur J Sport SciPetrie FJ, Woodward JS, McLeod S, West SW, Salmon D, Gardner AJ, Shill IJ, Romanchuk J, Dane K, Kitchin M, Jones B, Mackintosh KA, Starbuck C, Hendricks S, Philips G, Jones S, Tierney G, McNarry MA. +17 moreeuropepmc +1 more sourceDistinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes
Arthritis &Rheumatology, EarlyView.Objective
Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. The variable copy number (CN) of C4 genes and retroviral human endogenous retrovirus K (HERV‐K) element influence its function.Javier Martínez‐López, Carlos Rangel‐Peláez, Inmaculada Rodriguez‐Martin, Alfredo Guillen‐Del‐Castillo, Carmen P Simeón‐Aznar, José L Callejas, Oliver Distler, International SSc Group, P. Carreira, I. Castellvi, R. Ríos, N. Ortego‐Centeno, R. García Portales, A. Fernández‐Nebro, F. J. García‐Hernández, M. A. Aguirre, B. Fernández‐Gutiérrez, L. Rodríguez‐Rodríguez, P. García de la Peña, E. Vicente, J. L. Andreu, M. Fernández de Castro, F. J. López‐Longo, V. Fonollosa, G. Espinosa, C. Tolosa, A. Pros, L. Tío, E. Beltrán, M. Rodríguez Carballeira, F. J. Narváez, M. Rubio Rivas, V. Ortiz‐Santamaría, A. B. Madroñero, M. A. González‐Gay, B. Díaz, L. Trapiella, M. V. Egurbide, P. Fanlo‐Mateo, L. Saez‐Comet, F. Díaz, J. A. Roman‐Ivorra, J. J. Alegre Sancho, M. Freire, F. J. Blanco Garcia, N. Oreiro, T. Witte, G. Riemekasten, P. Airo, C. Magro, M. C. Vonk, R. Hesselstrand, A. Nordin, C. Lunardi, G. Moroncini, A. Gabrielli, A. Hoffmann‐Vold, J. H. W. Distler, Clinical Immunology, L. Padyukov, T. R. D. J. Radstake, G. Orozco, A. Barton, C. Fonseca, PRECISESADs Clinical Consortium, Barbara Vigone, Jacques‐Olivier Pers, Alain Saraux, Valérie Devauchelle‐Pensec, Divi Cornec, Sandrine Jousse‐Joulin, Bernard Lauwerys, Julie Ducreux, Anne‐Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Fátima Farinha, Miguel Angel González‐Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez‐Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Rafaela Ortega‐Castro, M Angeles Aguirre‐Zamorano, Alejandro Escudero‐Contreras, M. Carmen Castro‐Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López‐Berrio, Rocío Aguilar‐Quesada, Héctor Navarro‐Linares, Susanna M Proudman, Mandana Nikpour, Australian Scleroderma Interest Group (ASIG), A. Apostolopoulos, G.‐S. Ngian, J. Sahhar, Australia Victoria, N. Ferdowsi, D. Hansen, W. Stevens, L. V. Host, G. Major, A. Quinlivan, L. Ross, M. Tabesh, J. Walker, Nicolas Hunzelmann, Gianluca Moroncini, Jeska K de Vries‐Bouwstra, Ariane L Herrick, Yannick Allanore, Marta E. Alarcon‐Riquelme, Lorenzo Beretta, Shervin Assassi, Christopher P Denton, Maureen D Mayes, Javier Martin, Marialbert Acosta‐Herrera, Martin Kerick +156 morewiley +1 more sourceEfficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study
Arthritis &Rheumatology, EarlyView.Objective
The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods
Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators +12 morewiley +1 more sourceAnifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial
Arthritis &Rheumatology, EarlyView.Objective
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari +8 morewiley +1 more sourceBlended and digital approaches in histology and pathology teaching: A scoping review
Anatomical Sciences Education, EarlyView.Abstract
Histology and pathology education is evolving, driven by the integration of digital microscopy with other technological advances. Gaining insight into the impact of this transition, while understanding the perspectives of both students and educators, is important for improving teaching practices. This includes mapping teaching methods, digital Eleonora Nava, Ashis Jalote‐Parmar, Cecilie Våpenstad, Marit Valla +3 morewiley +1 more source